Unknown

Dataset Information

0

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.


ABSTRACT: BACKGROUND:Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models. PATIENTS AND METHODS:Patients with first recurrence/progression of glioblastoma were eligible for this early phase II and pharmacokinetic study exploring single-agent sagopilone (16 mg/m(2) over 3 h every 21 days). Primary end point was a composite of either tumor response or being alive and progression free at 6 months. Overall survival, toxicity and safety and pharmacokinetics were secondary end points. RESULTS:Thirty-eight (evaluable 37) patients were included. Treatment was well tolerated, and neuropathy occurred in 46% patients [mild (grade 1) : 32%]. No objective responses were seen. The progression-free survival (PFS) rate at 6 months was 6.7% [95% confidence interval (CI) 1.3-18.7], the median PFS was just over 6 weeks, and the median overall survival was 7.6 months (95% CI 5.3-12.3), with a 1-year survival rate of 31.6% (95% CI 17.7-46.4). Maximum plasma concentrations were reached at the end of the 3-h infusion, with rapid declines within 30 min after termination. CONCLUSIONS:No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected. Sagopilone was well tolerated, and moderate-to-severe peripheral neuropathy was observed in despite prolonged administration.

SUBMITTER: Stupp R 

PROVIDER: S-EPMC3164435 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

Stupp R R   Tosoni A A   Bromberg J E C JEC   Hau P P   Campone M M   Gijtenbeek J J   Frenay M M   Breimer L L   Wiesinger H H   Allgeier A A   van den Bent M J MJ   Bogdahn U U   van der Graaf W W   Yun H J HJ   Gorlia T T   Lacombe D D   Brandes A A AA  

Annals of oncology : official journal of the European Society for Medical Oncology 20110214 9


<h4>Background</h4>Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models.<h4>Patients and methods</h4>Patients with first recurrence/progression of glioblastoma were eligible for this early phase II and pharmacokinetic study exploring single-agent sagopilone (16 mg/m(2) over 3 h every 21 days). Primary end point was a composite of either tumor response or being alive and progression f  ...[more]

Similar Datasets

| S-EPMC8482129 | biostudies-literature
| S-EPMC9290884 | biostudies-literature
| S-EPMC3251849 | biostudies-literature
| S-EPMC2667826 | biostudies-literature
| S-EPMC6018571 | biostudies-literature
| 2359850 | ecrin-mdr-crc
| S-EPMC4433518 | biostudies-literature
| S-EPMC6960687 | biostudies-literature
| S-EPMC9071312 | biostudies-literature
| S-EPMC3499012 | biostudies-literature